Compare CDNA & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CDNA | ANNX |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | United States | United States |
| Employees | 765 | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 972.5M |
| IPO Year | 2007 | 2020 |
| Metric | CDNA | ANNX |
|---|---|---|
| Price | $21.55 | $5.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $28.00 | $16.50 |
| AVG Volume (30 Days) | 744.0K | ★ 2.0M |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $48,324,000.00 | N/A |
| Revenue This Year | $16.01 | N/A |
| Revenue Next Year | $11.31 | $16,320.74 |
| P/E Ratio | $430.00 | ★ N/A |
| Revenue Growth | ★ 18.93 | N/A |
| 52 Week Low | $10.96 | $1.85 |
| 52 Week High | $23.24 | $7.18 |
| Indicator | CDNA | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 58.59 | 41.02 |
| Support Level | $16.63 | $4.79 |
| Resistance Level | $23.19 | $5.61 |
| Average True Range (ATR) | 1.46 | 0.30 |
| MACD | -0.04 | -0.07 |
| Stochastic Oscillator | 66.57 | 15.79 |
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.